JP2016531913A - 神経抑制性ケタミンの単層による経口投与 - Google Patents

神経抑制性ケタミンの単層による経口投与 Download PDF

Info

Publication number
JP2016531913A
JP2016531913A JP2016537782A JP2016537782A JP2016531913A JP 2016531913 A JP2016531913 A JP 2016531913A JP 2016537782 A JP2016537782 A JP 2016537782A JP 2016537782 A JP2016537782 A JP 2016537782A JP 2016531913 A JP2016531913 A JP 2016531913A
Authority
JP
Japan
Prior art keywords
ketamine
naket
tablet composition
release time
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016537782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531913A5 (enExample
Inventor
アレックス ニヴォロジキン，
アレックス ニヴォロジキン，
ネルソン ランドロー，
ネルソン ランドロー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorsa Therapeutics Inc
Original Assignee
Amorsa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorsa Therapeutics Inc filed Critical Amorsa Therapeutics Inc
Publication of JP2016531913A publication Critical patent/JP2016531913A/ja
Publication of JP2016531913A5 publication Critical patent/JP2016531913A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2016537782A 2013-08-26 2014-08-26 神経抑制性ケタミンの単層による経口投与 Pending JP2016531913A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361869884P 2013-08-26 2013-08-26
US61/869,884 2013-08-26
US201462015513P 2014-06-22 2014-06-22
US62/015,513 2014-06-22
PCT/US2014/052786 WO2015031410A1 (en) 2013-08-26 2014-08-26 Single-layer oral dose of neuro-attenuating ketamine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020016717A Division JP2020079273A (ja) 2013-08-26 2020-02-04 神経抑制性ケタミンの単層による経口投与

Publications (2)

Publication Number Publication Date
JP2016531913A true JP2016531913A (ja) 2016-10-13
JP2016531913A5 JP2016531913A5 (enExample) 2017-10-05

Family

ID=52587281

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537782A Pending JP2016531913A (ja) 2013-08-26 2014-08-26 神経抑制性ケタミンの単層による経口投与
JP2020016717A Pending JP2020079273A (ja) 2013-08-26 2020-02-04 神経抑制性ケタミンの単層による経口投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020016717A Pending JP2020079273A (ja) 2013-08-26 2020-02-04 神経抑制性ケタミンの単層による経口投与

Country Status (5)

Country Link
US (4) US9913803B2 (enExample)
EP (2) EP3960162A1 (enExample)
JP (2) JP2016531913A (enExample)
CA (1) CA2922507C (enExample)
WO (1) WO2015031410A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536901A (ja) * 2017-10-10 2020-12-17 ダグラス・ファーマスーティカルズ・リミテッドＤｏｕｇｌａｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． 持続放出医薬製剤及び治療方法
JP2021529732A (ja) * 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
JP2022526233A (ja) * 2019-03-25 2022-05-24 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
EP3272338B1 (en) 2014-04-17 2020-09-09 Develco Pharma Schweiz AG Oral dosage form of ketamine
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
KR102604397B1 (ko) 2014-11-04 2023-11-21 아카디아 파마슈티칼스 인코포레이티드 신경 감쇠 케타민 및 노르케타민 화합물, 이의 유도체, 및 방법
CA2970065A1 (en) 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
MX2019012285A (es) * 2017-04-13 2020-11-06 Ovid Therapeutics Inc Metodos de tratamiento de encefalopatias del desarrollo.
EP3641742B1 (en) * 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
EP3934632A4 (en) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US12589083B2 (en) 2019-05-07 2026-03-31 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023543211A (ja) * 2020-09-24 2023-10-13 ダグラス ファーマシューティカルズ エルティーディー． 徐放性医薬製剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
US6194000B1 (en) * 1995-10-19 2001-02-27 F.H. Faulding & Co., Limited Analgesic immediate and controlled release pharmaceutical composition
JP2004520410A (ja) * 2001-02-27 2004-07-08 セフアロン・インコーポレーテツド 経口可溶性投与剤形のための組成物および製造方法
JP2004528338A (ja) * 2001-05-02 2004-09-16 ユーロ−セルティーク，エス．エイ． 一日に一回のオキシコドン製剤
US6855735B2 (en) * 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6216413A (ja) * 1985-07-12 1987-01-24 Teijin Ltd キチン類誘導体を用いた徐放性医薬品組成物
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US6492488B1 (en) * 1998-08-02 2002-12-10 Pmd Holdings Corp. Controlled release polyacrylic acid granules and a process for preparing the same
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
WO2003103603A2 (en) * 2002-06-10 2003-12-18 Wyeth Novel formate salt of o-desmethyl-venlafaxine
US20080027119A1 (en) * 2002-07-31 2008-01-31 Lippa Arnold S Methods and compositions employing bicifadine for the treatment of acute pain, chronic pain, and symptoms of neuropathic disorders
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
EP2139848A1 (en) 2007-04-26 2010-01-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
JP2015512418A (ja) * 2012-03-30 2015-04-27 ザ ジェネラル ホスピタル コーポレイション うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015040270A1 (en) 2013-09-23 2015-03-26 Convion Oy A recirculation arrangement and method for a high temperature cell system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
US6194000B1 (en) * 1995-10-19 2001-02-27 F.H. Faulding & Co., Limited Analgesic immediate and controlled release pharmaceutical composition
JP2004520410A (ja) * 2001-02-27 2004-07-08 セフアロン・インコーポレーテツド 経口可溶性投与剤形のための組成物および製造方法
JP2004528338A (ja) * 2001-05-02 2004-09-16 ユーロ−セルティーク，エス．エイ． 一日に一回のオキシコドン製剤
US6855735B2 (en) * 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICAL DRUG INVESTIGATION, vol. 29, no. 5, JPN6018017739, 2009, pages 317 - 324, ISSN: 0004128347 *
DRUG AND ALCOHOL DEPENDENCE, vol. 83, JPN6018017735, 2006, pages 247 - 254, ISSN: 0004128346 *
J. FORENSIC SCI., vol. 48, no. 6, JPN6018017737, November 2003 (2003-11-01), pages 1 - 11, ISSN: 0003934127 *
医療薬学, vol. 32, no. 4, JPN6018017733, 2006, pages 275 - 288, ISSN: 0004128345 *
薬学雑誌, vol. 119, no. 6, JPN6018017731, 1999, pages 980 - 987, ISSN: 0004128344 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536901A (ja) * 2017-10-10 2020-12-17 ダグラス・ファーマスーティカルズ・リミテッドＤｏｕｇｌａｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． 持続放出医薬製剤及び治療方法
JP7364558B2 (ja) 2017-10-10 2023-10-18 ダグラス ファーマシューティカルズ エルティーディー． 持続放出医薬製剤及び治療方法
JP2021529732A (ja) * 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
US12036189B2 (en) 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP7903800B2 (ja) 2018-06-27 2026-08-12 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP2022526233A (ja) * 2019-03-25 2022-05-24 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤
JP7381597B2 (ja) 2019-03-25 2023-11-15 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Also Published As

Publication number Publication date
EP3035918B1 (en) 2021-06-30
US9913803B2 (en) 2018-03-13
EP3035918A4 (en) 2017-03-29
US20160199304A1 (en) 2016-07-14
USRE50805E1 (en) 2026-02-24
CA2922507A1 (en) 2015-03-05
JP2020079273A (ja) 2020-05-28
US20180153813A1 (en) 2018-06-07
EP3960162A1 (en) 2022-03-02
US10653629B2 (en) 2020-05-19
US11554100B2 (en) 2023-01-17
CA2922507C (en) 2022-07-05
EP3035918A1 (en) 2016-06-29
US20200261370A1 (en) 2020-08-20
WO2015031410A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
JP2020079273A (ja) 神経抑制性ケタミンの単層による経口投与
EP0722730B2 (en) Controlled release oxycodone compositions
KR101784777B1 (ko) 타펜타돌 조성물
US10300141B2 (en) Tamper resistant dosage form comprising inorganic salt
US8758815B2 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
MXPA00012957A (es) Composicion para dosis oral de liberacion extendida.
KR20100129776A (ko) 왁스를 포함하는 서방형 제형
JP2005506367A (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
JP6444996B2 (ja) 調節放出製剤
CN107669649A (zh) 固体剂型
JP2017534613A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
KR20180016651A (ko) 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
KR20060108675A (ko) 서방성 약학 제형
WO2003082261A1 (en) Extended release venlafaxine formulations
RU2616263C2 (ru) Таблетка с замедленным высвобождением, содержащая леводропропизин, и способ ее изготовления
EP2269586A1 (en) Pharmaceutical composition comprising desloratadine
KR20080013927A (ko) 벤라팍스의 하나 이상 형태의 개질 방출 조성물
CA2295822A1 (en) Novel composition
KR20190075718A (ko) 용출율이 개선된 트라마돌 또는 이의 약학적으로 허용가능한 염 및 프레가발린 또는 이의 약학적으로 허용가능한 염을 포함하는 다층 제제
KR20080073342A (ko) 졸피뎀 정제
US20230028539A1 (en) Pharmaceutical composition, complementary kit and application thereof
KR101515222B1 (ko) 티아넵틴 나트륨 함유 제어방출성 경구용 단층 제제 및 이의 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191004